#376
|
|||
|
|||
Îò ñïàñèáêè...
|
#377
|
||||
|
||||
Êîëëåãè-õèðóðãè, àé íèä õåëï...
Ïåðåâîæó ñòàòüþ ïî ëå÷åíèþ ãíîéíûõ ðàí.  ðàçäåëå Ìàòåðèàëû è ìåòîäû âñòðåòèëîñü âîò òàêîå îïèñàíèå ñïîñîáà îöåíêè äèíàìèêè ñîñòîÿíèÿ ðàíû Photographs and acetate tracings of the wound edge were taken at either weekly or bi-weekly intervals ×òî çà ìåòîäèêà "acetate tracings"? Êàê ýòî íà íîðìàëüíûé ðóññêèé ïåðåâåñòè? |
#378
|
||||
|
||||
ñåé÷àñ îáüÿñíþ, êàê ýòî äåëàåòñÿ, áûòü ìîæåò Âàì ïðèéäåò íà óì ðóññêèé ýêâèâàëåíò...
ïðîçðà÷íàÿ (àöåòàòíàÿ) ïëåíêà (ðàçäåëåííàÿ íà êâàäðàòèêè) ïðèêëàäûâàåòñÿ ê ðàíå è êðàÿ ðàíû îáâîäÿòñÿ ïåðìàíåíòíûì ìàðêåðîì, ïîòîì ñ÷èòàåòñÿ ðàçìåð ðàíû ïî êâàäðàòàì (êâàäðàòíûì ñàíòèìåòðàì?) - ïîâòîðíûå îöåíêè âî âðåìåíè ïîçâîëÿþò îöåíèòü äèíàìèêó çàæèâëåíèÿ ðàíû...
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#379
|
||||
|
||||
âîò êàê ýòî âûãëÿäèò íà ôîòêàõ...
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#380
|
||||
|
||||
âîò òàêîé âîëüíûé ïåðåâîä ïîëó÷èëñî... "äèíàìè÷åñêàÿ îöåíêà ïîâåðõíîñòè (ïëîùàäè?) ðàíû ñ ïîìîùüþ ïðîçðà÷íîé ðàçëèíååííîé ïëåíêè"
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#382
|
||||
|
||||
Ïðîçðà÷íóþ ðàçëèíååíóþ ïëåíêó äëÿ îöåíêè ïëîùàäè íåïðàâèëüíûõ ôèãóð èíîãäà äëÿ êðàòêîñòè íàçûâàþò ïàëåòêîé. Òåðìèí îôèöèàëüíûé.
|
#383
|
|||
|
|||
Äîáðîé íî÷è!
×òî àâòîðû èìåëè ââèäó? The heterogeneous advanced RCC patient population in EU-ARCCS permitted assessment of sorafenib in important subpopulations of advanced RCC patients. |
#384
|
||||
|
||||
Áûëî áû íåïëîõî óçíàòü ðàñøèôðîâêó àááðåâèàòóð äëÿ áîëåå òî÷íîé ôîðìóëèðîâêè, à òàê: "Ãåòåðîãåííîñòü/ðàçíîðîäíîñòü ïîïóëÿöèè ïàöèåíòîâ ñ çàïóùåííîé ôîðìîé ÐÖÖ â òðàéëå åâðî-ÀÐÖÖÑ ïîçâîëèëà îöåíèòü ýôôåêòèâíîñòü ñîðàôåíèáà â âàæíûõ ïîäêëàññàõ/ïîäâèäàõ ïàöèåíòîâ ñ çàïóùåííîé ôîðìîé ÐÖÖ"
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#385
|
|||
|
|||
renal cell cancer
Àãà, â ðàçíîøåðñòíîé òîëïå ìû ìîãëè îöåíèòü ðîëü ãàëñòóêà äëÿ ïðåäåëåííûõ êîíòèíãåíòîâ .... Ñïñ :-) |
#386
|
|||
|
|||
Äîáðîãî óòðà(?) âñåì.
Ê íî÷è óæå òóïëþ: Non-inferiority was considered to be established, if the treatment difference in adjusted mean percentage reduction was significantly greater than Δ = − 10 points in both the FAS and PP analysis sets (two-sided at α = 0.05). Ñïñ. |
#387
|
||||
|
||||
íå õóäøèì ëå÷åíèåì ñ÷èòàëîñü, åñëè ðàçíèöà â ëå÷åíèè áûëà çíà÷èòåëüíî áîëüøå äåëüòû â ìèíóñ 10 ïóíêòîâ ïî ñðåäíåìó ñíèæåíèþ ïðîöåíòà êàê ïðè àíàëèçå ÔÀÑ òàê è ÏÏ
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#388
|
||||
|
||||
Êîëëåãè, õåëï ìè ïëèç. ß ñîâñåì ñëîìàëà ìîçã.
If outcomes in patients with CF are to continue to improve there is a need for simplification of treatment delivery, and improved understanding of the effectiveness of interventions, including the utility of technology to enhance information, communication and adherence and to help standardize and individualize care.  ñòàòüå ðå÷ü èäåò î ñëîæíîñòÿõ âåäåíèÿ ïàöèåíòîâ ñ ìóêîâèñöèäîçîì, â ÷àñòíîñòè, î òðóäíîñòè òî÷íîãî äîçèðîâàíèÿ ïðåïàðàòîâ ïðè íåáóëàéçåðíîé òåðàïèè â äîìàøíèõ óñëîâèÿõ. |
#389
|
||||
|
||||
"Åñëè åñòü æåëàíèå/öåëü ïðîäîëæàòü óëó÷øàòü èñõîä/ïðîãíîç ó ïàöèåíòîâ ñ CF, òî íåîáõîäèìî óïðîñòèòü ñïîñîá äîñòàâêè ëå÷åíèÿ è óëó÷øèòü ïîíèìàíèå ýôôåêòèâíîñòè âìåøàòåëüñòâ, âêëþ÷àÿ ïðèìåíåíèå òåõíîëîãèè óëó÷øåíèÿ (ïîäà÷è) èíôîðìàöèè è îáùåíèÿ (ñ ïàöèåíòîì), ïðèâåðæåííîñòè ê ëå÷åíèþ, à òàêæå ïîìîãàòü ñòàíäàðòèçèðîâàòü è èíäèâèäóàëèçèðîâàòü òåðàïèþ."
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |